Upstream To Downstream: A Comprehensive Approach To AAV Production

The gene therapy industry is facing challenges in producing high titer Adeno-Associated Virus (AAV) at clinical and commercial scales within strict timelines. Paula Decaria and Chiu Lau-Barre from Thermo Fisher Scientific discuss strategies to meet growing AAV production demands and answer related queries. The webinar will address issues in scaling up AAV manufacturing, facilitating AAV production using single-use bioreactors at different scales, and methods to enhance recovery and purity in downstream processing.